Combination therapy with GLP ‐1 receptor agonists and basal insulin: a systematic review of the literature-Reference-Cited by-同舟云学术

Combination therapy with GLP ‐1 receptor agonists and basal insulin: a systematic review of the literature

Published:2012-11-12 Issue:6 Volume:15 Page:485-502
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Balena R.¹,Hensley I. E.²,Miller S.³,Barnett A. H.⁴

Affiliation:

1. Eli Lilly and Company Ltd Erl Wood Manor Windlesham Surrey UK

2. Eli Lilly and Company Indianapolis IN USA

3. Amylin Pharmaceuticals LLC San Diego CA USA

4. University of Birmingham and Diabetes Centre Heart of England NHS Foundation Trust Birmingham UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.12025

Reference79 articles.

1. New Perspectives in Type 2 Diabetes, Cardiovascular Risk, and Treatment Goals

2. Management of hyperglycemia in type 2 diabetes: a patient‐centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Inzucchi SE;Diabetes Care,2012

3. Response to Intensive Therapy Steps and to Glipizide Dose in Combination With Insulin in Type 2 Diabetes: VA feasibility study on glycemic control and complications (VA CSDM)

4. The impact of diabetes and associated cardiometabolic risk factors on members: Strategies for optimizing outcomes;Hoerger TJ;J Manag Care Pharm,2008

5. Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999–2004

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials;Diabetes, Obesity and Metabolism;2024-09-08

2. From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists;Molecular Biology Reports;2024-07-23

3. Real-world effectiveness of iGlarLixi in individuals with T2D sub-optimally controlled on oral anti-diabetic drugs with or without basal insulin in daily practice in Saudi Arabia (EMPOWER study);Endocrine and Metabolic Science;2024-06

4. Real‐world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12‐month, prospective observational study;Diabetes, Obesity and Metabolism;2024-04-18

5. Coordinated ASBT and EGFR Mechanisms for Optimized Liraglutide Nanoformulation Absorption in the GI Tract;International Journal of Nanomedicine;2024-03